OrbusNeich Med Grp Hldg Ltd (6929) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of OrbusNeich Med Grp Hldg Ltd HK$6.25, price HK$3.76, upside +66.2%, quality 60 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch OrbusNeich Med Grp Hldg Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
45‑month range HK$2.61 – HK$12.53 · fair‑value band HK$4.15 – HK$9.16 · the HK$3.76 price screens below the HK$6.25 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Follow OrbusNeich Med Grp Hldg in your weekly email
Every Wednesday you see whether OrbusNeich Med Grp Hldg is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
OrbusNeich Medical Group Holdings Limited, an investment holding company, engages in the manufacture, trading, sale, and marketing of medical devices/instruments for the treatment of coronary and peripheral vascular diseases.
Show more
OrbusNeich Medical Group Holdings Limited, an investment holding company, engages in the manufacture, trading, sale, and marketing of medical devices/instruments for the treatment of coronary and peripheral vascular diseases. The company offers semi-compliant balloons and scoring balloons for pre-dilatation and lesion preparation, drug-coated balloons and stents for lesion therapy, non-compliant balloons for post-dilatation, and specialty catheters, as well as microcatheters, guide catheter extension, dual therapy, and drug eluting stents. Its product portfolio covers various treatment processes in percutaneous coronary intervention and percutaneous transluminal angioplasty procedures. It operates in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People's Republic of China, the United States, and internationally. The company was founded in 2001 and is headquartered in Sha Tin, Hong Kong. OrbusNeich Medical Group Holdings Limited is a subsidiary of Harmony Tree Limited.
Stock analysis
OrbusNeich Med Grp Hldg Ltd (6929) currently trades at HK$3.76, while our model-based Fair Value estimate is HK$6.25, implying the stock looks roughly 39.8% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of HK$0.9600 per share, and 0 of the 25 models we run sit above the HK$3.76 price.
Bear case: the DCF Models group reads lowest at HK$0.8200, and 25 of the 25 models stay below the price. Evidence for this calculation is low.
Scenario range: HK$4.15 (bear) to HK$9.16 (bull), the price of HK$3.76 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 60/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
OrbusNeich Med Grp Hldg Ltd reported revenue of $180M in FY2025 versus $116M in FY2021, a compound +11.6%/yr. Reported net income was $41.9M in FY2025.
Key figures
Market cap HK$3.1B (≈ $396M) · P/E ratio 9.6 · P/S ratio 2.23 · EPS (TTM) HK$0.0200 · Dividend yield 0.4% · Net margin 23.2% · Return on equity 10.4% · Return on assets (EBIT) 7.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 22% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −13% fair-value upside, at 66%, 6929 screens cheaper than that median.
Fair Value models
Bear HK$4.15Fair Value HK$6.25Bull HK$9.16
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (HK$0.0037 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+10.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.3%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.0%
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+33.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+33.1%
Dividend (yield on the price)0.4%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.10% → 22%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+57.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (figures in USD, USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +53.8% a year for the price.
Compare OrbusNeich Med Grp Hldg Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 204 stocks
Beats the industry median on 12/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score60 · Above median
Fair Value upside+66% · Top 25%
Profitability
Return on equity (TTM)10% · Above median
Return on assets6% · Above median
Net margin (TTM)23% · Top 25%
Operating margin (TTM)24% · Top 25%
Growth and dividend
Revenue growth14% · Above median
Dividend yield (TTM)0.4% · Bottom 25%
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "OrbusNeich Med Grp Hldg Ltd Fair Value". https://www.fairvalue-calculator.com/stock/6929
Frequently asked questions
Is OrbusNeich Med Grp Hldg Ltd (6929) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of HK$6.25 versus a price of HK$3.76, about +66% upside (undervalued).
What is the fair value of 6929?
Our model-based fair value for OrbusNeich Med Grp Hldg Ltd is HK$6.25 (as of Sep 24, 2026), built from audited fundamentals. The current price: HK$3.76.
What is the quality score of 6929?
OrbusNeich Med Grp Hldg Ltd has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for OrbusNeich Med Grp Hldg Ltd (6929)?
Our model-based price target is the fair value of HK$6.25 (as of Sep 24, 2026) from 25 valuation models. Cautious scenario HK$4.15, optimistic scenario HK$9.16. It is a calculation from audited fundamentals, not an analyst target.
What is the OrbusNeich Med Grp Hldg Ltd stock forecast for 2026?
Our models put fair value at HK$6.25, about +66% upside versus a price of HK$3.76 (undervalued). Cautious scenario HK$4.15, optimistic scenario HK$9.16. The calculation is refreshed regularly with new filings.
What is the revenue of OrbusNeich Med Grp Hldg Ltd (6929)?
OrbusNeich Med Grp Hldg Ltd reported trailing-twelve-month revenue of about $180M (latest available figure, as of Sep 24, 2026).
Does OrbusNeich Med Grp Hldg Ltd pay a dividend?
OrbusNeich Med Grp Hldg Ltd currently shows a dividend yield of about 0.40% relative to its recent price (as of Sep 24, 2026).
What growth is priced into OrbusNeich Med Grp Hldg Ltd (6929)?
For today's price to be fair in a discounted-cash-flow model, OrbusNeich Med Grp Hldg Ltd would have to grow free cash flow by +57.4 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +15.3 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 6929 use?
Our models discount OrbusNeich Med Grp Hldg Ltd at 11.8 %: a base by market capitalisation (small), country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For OrbusNeich Med Grp Hldg Ltd that is +57.4 % per year a year over ten years, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has OrbusNeich Med Grp Hldg Ltd (6929) delivered so far?
Over the past 5 years revenue at OrbusNeich Med Grp Hldg Ltd grew +15.3 % a year. The price currently implies +57.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of OrbusNeich Med Grp Hldg Ltd (6929) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into OrbusNeich Med Grp Hldg Ltd (+57.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of OrbusNeich Med Grp Hldg Ltd (6929)?
The free-cash-flow yield on the price is 0.29 %: that much free cash flow OrbusNeich Med Grp Hldg Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of OrbusNeich Med Grp Hldg Ltd (6929)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For OrbusNeich Med Grp Hldg Ltd it is HK$6.25 per share (as of Sep 24, 2026), against a price of HK$3.76. It is the blended result of 25 valuation models (cash flow, earnings, asset, dividend).
Is OrbusNeich Med Grp Hldg Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 6929 trades below its calculated fair value: price HK$3.76, fair value HK$6.25, a gap of about +66% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6929?
No. The price is what the market pays today (HK$3.76); the fair value is what the company's own numbers justify (HK$6.25). For OrbusNeich Med Grp Hldg Ltd the two are HK$2.49 per share apart. That gap is exactly why we show both numbers side by side.
How much is OrbusNeich Med Grp Hldg Ltd worth?
The market values OrbusNeich Med Grp Hldg Ltd at about HK$3.1B (market capitalisation, as of Sep 24, 2026). Per share that is HK$3.76; our models calculate a fair value of HK$6.25 per share.
What do the bullish and bearish scenarios say about 6929?
Our models span a range for OrbusNeich Med Grp Hldg Ltd: cautious scenario HK$4.15, base HK$6.25, optimistic HK$9.16 per share (as of Sep 24, 2026, price HK$3.76). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 6929?
OrbusNeich Med Grp Hldg Ltd trades at a price-to-earnings ratio of 9.6 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$6.25 is built from several models across several years. Other multiples: PEG 0.7, P/B 1.0, P/S 2.2, EV/EBITDA 4.1.
What is the PEG ratio of 6929?
The PEG ratio of OrbusNeich Med Grp Hldg Ltd is 0.71 (P/E divided by earnings growth, as of Sep 24, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of OrbusNeich Med Grp Hldg Ltd (6929)?
Balance-sheet figures for OrbusNeich Med Grp Hldg Ltd (as of Sep 24, 2026): return on equity 10.4%. They feed the Quality Score of 60/100, which measures business quality independently of the share price.
How far is 6929 from its 52-week high?
OrbusNeich Med Grp Hldg Ltd trades at HK$3.76, about 22% below its 52-week high of HK$4.83 and 10% above the low of HK$3.42 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of HK$6.25 is for.
Which stocks are comparable to OrbusNeich Med Grp Hldg Ltd?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Medline Inc, Becton, Dickinson and Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is OrbusNeich Med Grp Hldg Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price HK$3.76, calculated fair value HK$6.25 (+66%), Quality Score 60/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6929 calculated?
We run OrbusNeich Med Grp Hldg Ltd through 25 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$6.25, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. OrbusNeich Med Grp Hldg Ltd currently trades 66 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of OrbusNeich Med Grp Hldg Ltd (6929)?
The closing price on Sep 24, 2026 was HK$3.76. Our model-based fair value is HK$6.25, about +66% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with OrbusNeich Med Grp Hldg Ltd right now?
The price is below even our cautious bear case (HK$4.15). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (60/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (HK$4.15 to HK$9.16) leaves room in how you read the outcome.
Key figures of OrbusNeich Med Grp Hldg Ltd
How large is the market capitalisation of OrbusNeich Med Grp Hldg Ltd (6929)?
The market capitalisation of OrbusNeich Med Grp Hldg Ltd is HK$3.1B (≈ $396M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of OrbusNeich Med Grp Hldg Ltd (6929)?
The price-to-sales ratio of OrbusNeich Med Grp Hldg Ltd is 2.23 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of OrbusNeich Med Grp Hldg Ltd (6929)?
Earnings per share at OrbusNeich Med Grp Hldg Ltd are HK$0.0200 (price ÷ EPS = P/E 9.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of OrbusNeich Med Grp Hldg Ltd (6929)?
The dividend yield of OrbusNeich Med Grp Hldg Ltd is 0.4% (payout 75.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of OrbusNeich Med Grp Hldg Ltd (6929)?
The net margin of OrbusNeich Med Grp Hldg Ltd is 23.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of OrbusNeich Med Grp Hldg Ltd (6929)?
The return on equity (ROE) of OrbusNeich Med Grp Hldg Ltd is 10.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of OrbusNeich Med Grp Hldg Ltd (6929)?
On an EBIT basis the return on assets of OrbusNeich Med Grp Hldg Ltd is 7.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of OrbusNeich Med Grp Hldg Ltd (6929)?
The operating margin of OrbusNeich Med Grp Hldg Ltd is 24.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at OrbusNeich Med Grp Hldg Ltd (6929)?
Revenue at OrbusNeich Med Grp Hldg Ltd is growing +13.8% versus a year earlier (3y avg +9.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at OrbusNeich Med Grp Hldg Ltd (6929)?
Earnings per share at OrbusNeich Med Grp Hldg Ltd are growing +5.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does OrbusNeich Med Grp Hldg Ltd (6929) hold?
OrbusNeich Med Grp Hldg Ltd holds more cash than debt, $215M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch OrbusNeich Med Grp Hldg Ltd in the live analysis
One click puts OrbusNeich Med Grp Hldg Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
